SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on May 21, 2008, reporting events occurring on May 15, 2008. The filing details the entry into a material definitive agreement regarding the company's capital structure and financing options.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt. The only specific financial figures disclosed relate to a potential future investment:
- Maximum Put Amount: Up to $1,500,000.
- Purchase Price: $0.55 per share of common stock.
- Counterparty: Gian Luigi Longinetti-Buitoni (Executive Chairman and Lead Investor).
Material Changes
The primary material change is the execution of Amendment No. 5 to the Warrant and Put Option Agreement originally dated November 30, 2006. This amendment extends the deadline for the Company to exercise a put option requiring the Lead Investor to purchase additional units. The new expiration date for exercising this option is June 1, 2008.
Outlook, Risks, and Management Commentary
Management has secured the ability to raise up to $1.5 million in additional capital by June 1, 2008, subject to the Company's sole discretion to exercise the put option. If exercised, the Lead Investor is obligated to purchase the specified units by June 2, 2008. The filing does not contain explicit forward-looking guidance, risk factors, or commentary on unusual items beyond the terms of this amendment.
Investor Verification Checklist
- Verify the current cash position of Xenomics, Inc. to assess the likelihood of exercising the put option.
- Confirm the total number of shares outstanding to calculate the potential dilution from the $1.5 million investment at $0.55 per share.
- Review the full text of Amendment No. 5 (Exhibit 4.1) for any covenants or conditions precedent not summarized in the 8-K.
- Check subsequent filings to determine if the put option was exercised by the June 1, 2008 deadline.